427
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluation

An evaluation of mepolizumab for the treatment of severe asthma

, , , &
Pages 491-500 | Received 31 Jan 2019, Accepted 18 Apr 2019, Published online: 07 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Federica Porcaro, Renato Cutrera & Giovanni Battista Pajno. (2019) Options of immunotherapeutic treatments for children with asthma. Expert Review of Respiratory Medicine 13:10, pages 937-949.
Read now

Articles from other publishers (3)

Ken Fukuda, Tatsuma Kishimoto, Tamaki Sumi, Kenji Yamashiro & Nobuyuki Ebihara. (2023) Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye. Allergology International 72:2, pages 234-244.
Crossref
Hale ATEŞ, Kurtuluş AKSU, İlkay KOCA KALKAN, Musa TOPEL, Senay DEMİR, Selma YESİLKAYA & Sakine NAZİK BAHCECİOGLU. (2022) Evaluation of real-life data in patients with severe eosinophilic asthma treated with mepolizumabMepolizumab ile tedavi edilen ağır eozinofilik astımlı hastalarda gerçek yaşam verilerinin değerlendirilmesi. Journal of Medicine and Palliative Care 3:3, pages 275-279.
Crossref
Jamie L. Redes, Trisha Basu, Sumati Ram-Mohan, Chandra C. Ghosh, Eunice C. Chan, Albert C. Sek, Ming Zhao, Ramaswamy Krishnan, Helene F. Rosenberg & Kirk M. Druey. (2019) Aspergillus fumigatus –Secreted Alkaline Protease 1 Mediates Airways Hyperresponsiveness in Severe Asthma . ImmunoHorizons 3:8, pages 368-377.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.